Epilepsy Trial, Recruiting NCT06555965 Sponsor: Children's Hospital of Philadelphia Condition: Epilepsy
Back to Epilepsy

Epilepsy Trial, Recruiting

NCT06555965
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People of any age, either male or female, may be considered.
  • People who have a confirmed mutation in either the STXBP1 or SYNGAP1 gene, where that mutation has been classified as causing their condition based on clinical and genetic assessment criteria. Past genetic test results may be sufficient to support this.

Who may not be able to join:

  • People who have a confirmed mutation in a gene other than STXBP1 or SYNGAP1 that is known to cause a neurodevelopmental disability.
  • People whose STXBP1 or SYNGAP1 gene deletion is large enough to also affect other nearby genes beyond just STXBP1 or SYNGAP1.
  • People who have a significant brain or behavioural condition unrelated to their STXBP1 or SYNGAP1 mutation that could affect how results are interpreted.
  • People who have a history of bleeding inside the fluid-filled spaces of the brain (intraventricular hemorrhage), a structural brain difference, or a heart condition present from birth.
  • People who have another health condition that, in the trial doctor's judgement, could interfere with the typical features of an STXBP1 or SYNGAP1-related condition.
  • Females who are pregnant, or females who have started menstruating and test positive for pregnancy at the time of screening.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ingo Helbig, MD, Children's Hospital of Philadelphia

Phone: 2674411813

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Children's Hospital of Philadelphia
Registry
ClinicalTrials.gov
Start date
30 August 2023
Est. completion
30 August 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Changes in percentiles recorded on clinical assessments over time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov